<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156362</url>
  </required_header>
  <id_info>
    <org_study_id>2011.665</org_study_id>
    <nct_id>NCT02156362</nct_id>
  </id_info>
  <brief_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</brief_title>
  <official_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is generally estimated that 5 % of patients with thyroid cancer will develop distant&#xD;
      metastases, and most of them had an advanced stage of the disease at presentation. Thirty per&#xD;
      cent of them are resistant to radio iodine therapy and are called &quot;refractory&quot;. Their long&#xD;
      term survival is estimated to be less than 10 %.&#xD;
&#xD;
      The objective of this study is to identify the factors associated with poor outcome in a&#xD;
      cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and&#xD;
      medullary thyroid carcinomas were excluded.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Thyroid cancer evolving to refractory stage</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">643</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follow up visit</intervention_name>
    <description>At least 1 follow up visit per year will be done and an additional visit if needed.</description>
    <arm_group_label>follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman ≥ 18 years.&#xD;
&#xD;
          -  Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly&#xD;
             differentiated carcinoma).&#xD;
&#xD;
          -  TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.&#xD;
&#xD;
          -  Patient after post operative radioiodine therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who can not be followed during the protocol.&#xD;
&#xD;
          -  Patient who does not consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire BOURNAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid carcinoma</keyword>
  <keyword>predictive factors</keyword>
  <keyword>refractory</keyword>
  <keyword>Differentiated</keyword>
  <keyword>follicular origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

